Exendin-4 antagonizes Aβ1-42-induced suppression of long-term potentiation by regulating intracellular calcium homeostasis in rat hippocampal neurons

Brain Research

Volumn 1627, Issue , 2015, Pages 101-108

  Wang, Xiaohui ^a   Wang, Li ^a   Jiang, Ruirui ^a   Yuan, Yuan ^a   Yu, Qianqian ^a   Li, Yameng ^b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

A 1 42; Calcium homeostasis; Exendin 4; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II ALPHA; EXENDIN 4; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; 2-AMINO-5-PHOSPHOPENTANOIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTIDIABETIC AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; PEPTIDE; PEPTIDE FRAGMENT; VALINE; VENOM;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRAHIPPOCAMPAL DRUG ADMINISTRATION; LONG TERM POTENTIATION; MALE; NEUROPROTECTION; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CONFOCAL MICROSCOPY; CYTOLOGY; DRUG EFFECTS; ELECTROSTIMULATION; HIPPOCAMPUS; HOMEOSTASIS; METABOLISM; NERVE CELL; PATCH CLAMP TECHNIQUE; SPRAGUE DAWLEY RAT; TIME FACTOR;

AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; ELECTRIC STIMULATION; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; LONG-TERM POTENTIATION; MICROSCOPY, CONFOCAL; NEURONS; NIFEDIPINE; PATCH-CLAMP TECHNIQUES; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VALINE; VENOMS;

EID: 84954243560     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.09.015     Document Type: Article

References (53)

1. 2+ signals and neuronal death in brain ischemia Stroke 38 2007 674 676
2. M. Baudry, G. Zhu, Y. Liu, Y. Wang, V. Briz, and X. Bi Multiple cellular cascades participate in long-term potentiation and in hippocampus-dependent learning Brain Res. 1621 2015 73 81
3. T. Bejan-Angoulvant, J. Crochet, and A.P. Jonville-Bera Calcium channel blockers pharmacology and their use as tocolytics J. Gynecol. Obstet. Biol. Reprod. 44 2015 305 311
4. M.J. Berridge Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia Prion 7 2013 2 13
5. D.S. Carter, S.N. Haider, R.E. Blair, L.S. Deshpande, S. Sombati, and R.J. DeLorenzo Altered calcium/calmodulin kinase II activity changes calcium homeostasis that underlies epileptiform activity in hippocampal neurons in culture J. Pharmacol. Exp. Ther. 319 2006 1021 1031
6. J. Chen, F.M. Couto, A.H. Minn, and A. Shalev Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein Biochem. Biophys. Res. Commun. 346 2006 1067 1074
7. W.K. Cullen, Y.H. Suh, R. Anwyl, and M.J. Rowan Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments Neuroreport 8 1997 3213 3217
8. T.A. Dar, I.A. Sheikh, S.A. Ganie, R. Ali, L.R. Singh, S.H. Gan, M.A. Kamal, and M.A. Zargar Molecular linkages between diabetes and Alzheimers disease: current scenario and future prospects CNS Neurol. Disord. Drug Targets 13 2014 290 298
9. R.J. Delorenzo, D.A. Sun, and L.S. Deshpande Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintainance of epilepsy Pharmacol. Ther. 105 2005 229 266
10. i is sufficient but not necessary for driving mitosis in early mouse embryos J. Cell. Sci. 118 2005 4563 4575
11. A.C. Fonseca, P.I. Moreira, C.R. Oliveira, S.M. Cardoso, P. Pinton, and C.F. Pereira Amyloid-beta disrupts calcium and redox homeostasis in brain endothelial cells Mol. Neurobiol. 51 2015 610 622
12. V.A. Gault, W.D. Porter, P.R. Flatt, and C. Holscher Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet Int. J. Obes. 34 2010 1341 1344
13. M. Haghani, M. Shabani, and M. Tondar The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Aβ neurotoxicity Eur. J. Pharmacol. 758 2015 82 88
14. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics Science 297 2002 353 356
15. S.C. Hopp, H.M. DAngelo, S.E. Royer, R.M. Kaercher, A.M. Crockett, L. Adzovic, and G.L. Wenk Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation J. Neuroinflamm. 12 2015 56
16. K.M. Huber, M.D. Mauk, and P.T. Kelly Distinct LTP induction mechanisms: contribution of NMDA receptors and voltage-dependent calcium channels J. Neurophysiol. 73 1995 270 279
17. Y. Ikegaya, H. Saito, and K. Abe Amygdala N-methyl-D-aspartate receptors participate in the induction of long-term potentiation in the dentate gyrus in vivo Neurosci. Lett. 192 1995 193 196
18. A.J. Kastin, and V. Akerstrom Entry of exendin-4 into brain is rapid but may be limited at high doses Int. J. Obes. Relat. Metab. Disord. 27 2003 313 318
19. T.H. Kim, C.W. Park, H.Y. Kim, M.H. Chi, S.K. Lee, Y.M. Song, H.H. Jiang, S.M. Lim, Y.S. Youn, and K.C. Lee Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice Biol. Pharm. Bull. 35 2012 1076 1083
20. P.S. Koekkoek, L.J. Kappelle, E. van den Berg, G.E. Rutten, and G.J. Biessels Cognitive function in patients with diabetes mellitus: guidance for daily care Lancet Neurol. 14 2015 329 340
21. K.V. Kuchibhotla, S.T. Goldman, C.R. Lattarulo, H.Y. Wu, B.T. Hyman, and B.J. Bacskai Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks Neuron 59 2008 214 225
22. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, T.E. Morgan, I. Rozovsky, B. Trommer, K.L. Viola, P. Wals, C. Zhang, C.E. Finch, G.A. Krafft, and W.L. Klein Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. USA 95 1998 6448 6453
23. 2+ desensitizing troponin in a transgenic mouse model of restrictive cardiomyopathy J. Mol. Cell. Cardiol. 49 2010 402 411
24. S. Ma, H. Liu, H. Jiao, L. Wang, L. Chen, J. Liang, M. Zhao, and X. Zhang Neuroprotective effect of ginkgolide K on glutamate-induced cytotoxicity in PC 12 cells via inhibition of ROS generation and Ca(2+) influx Neurotoxicology 33 2012 59 69
25. R.C. Malenka, and M.F. Bear LTP and LTD: an embarrassment of riches Neuron 44 2004 5 21
26. A.K. Mantha, K. Moorthy, S.M. Cowsik, and N.Z. Baquer Neuroprotective role of neurokinin B (NKB) on beta-amyloid (25-35) induced toxicity in aging rat brain synaptosomes: involvement in oxidative stress and excitotoxicity Biogerontology 7 2006 1 17
27. A.R. Meloni, M.B. DeYoung, J. Han, J.H. Best, and M. Grimm Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals Cardiovasc. Diabetol. 12 2013 48
28. E. Miyamoto Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus J. Pharmacol. Sci. 100 2006 433 442
29. S.L. Morgan, and T.J. Teyler VDCCs and NMDARs underlie two forms of LTP in CA1 hippocampus in vivo J. Neurophysiol. 82 1999 736 740
30. G. Mushtaq, J.A. Khan, and M.A. Kamal Biological mechanisms linking Alzheimers disease and type-2 diabetes mellitus CNS Neurol. Disord. Drug Targets 13 2014 1192 1201
31. 2+ homeostasis J. Biol. Chem. 287 2012 31674 31680
32. 2+]i levels occur with decreased calpain activity in aged fibroblasts and their reversal by energy-rich compounds: new paradigm for Alzheimers disease prevention J. Alzheimers Dis. 37 2013 835 848
33. V. Nimmrich, and A. Eckert Calcium channel blockers and dementia Br. J. Pharmacol. 169 2013 1203 1210
34. A. Nitta, T. Fukuta, T. Hasegawa, and T. Nabeshima Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration Jpn. J. Pharmacol. 73 1997 51 57
35. E. OHare, D.T. Weldon, P.W. Mantyh, J.R. Ghilardi, M.P. Finke, M.A. Kuskowski, J.E. Maggio, R.A. Shephard, and J. Cleary Delayed behavioral effects following intrahippocampal injection of aggregated Abeta (1-42) Brain Res. 815 1999 1 10
36. T. Perry, D.K. Lahiri, D. Chen, J. Zhou, K.T. Shaw, J.M. Egan, and N.H. Greig A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells J. Pharmacol. Exp. Ther. 300 2002 958 966
37. T. Perry, D.K. Lahiri, K. Sambamurti, D. Chen, M.P. Mattson, J.M. Egan, and N.H. Greig Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron J. Neurosci. Res. 72 2003 603 612
38. S.D. Rege, T. Geetha, T.L. Broderick, and J.R. Babu Resveratrol protects beta amyloid-induced oxidative damage and memory associated proteins in H19-7 hippocampal neuronal Cells Curr. Alzheimer Res. 12 2015 147 156
39. D. Riccardi, and P.J. Kemp The calcium-sensing receptor beyond extracellular calcium homeostasis: conception, development, adult physiology, and disease Annu. Rev. Physiol. 74 2012 271 297
40. C.M. Ryan, and M. Geckle Why is learning and memory dysfunction in type 2 diabetes limited to older adults? Diabetes Metab. Res. Rev. 16 2000 308 315
41. G. Sharma, and S. Vijayaraghavan Modulation of presynaptic store calcium induces release of glutamate and postsynaptic firing Neuron 38 2003 929 939
42. O.A. Shipton, J.R. Leitz, J. Dworzak, C.E. Acton, E.M. Tunbridge, F. Denk, H.N. Dawson, M.P. Vitek, R. Wade-Martins, O. Paulsen, and M. Vargas-Caballero Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation J. Neurosci. 31 2011 1688 1692
43. 2+/calmodulin-dependent protein kinase II J. Biol. Chem. 276 2001 3719 3722
44. +/CaMK II level in senescence-accelerated mice Zhongguo Zhong Xi Yi Jie He Za Zhi. 31 2011 376 380
45. D.J. Surmeier, J.N. Guzman, J. Sanchez-Padilla, and P.T. Schumacker The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinsons disease Neuroscience 198 2011 221 231
46. F. Trudeau, S. Gagnon, and G. Massicotte Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus Eur. J. Pharmacol. 490 2004 177 186
47. 2+ overload indicates early neuronal injury which precedes staining with viability indicators Brain Res. 607 1993 319 323
48. X.H. Wang, L. Li, C. Holscher, Y.F. Pan, X.R. Chen, and J.S. Qi Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats Neuroscience 170 2010 1239 1248
49. X.H. Wang, W. Yang, C. Holscher, Z.J. Wang, H.Y. Cai, Q.S. Li, and J.S. Qi Val(8)-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid beta peptide in rats J. Neurosci. Res. 91 2013 568 577
50. N.K. Woods, and J. Padmanabhan Neuronal calcium signaling and Alzheimers disease Adv. Exp. Med. Biol. 740 2012 1193 1217
51. W. Xu, Y. Yang, G. Yuan, W. Zhu, D. Ma, and S. Hu Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes J. Investig. Med. 63 2015 267 272
52. J.T. Yu, R.C. Chang, and L. Tan Calcium dysregulation in Alzheimers disease: from mechanisms to therapeutic opportunities Prog. Neurobiol. 89 2009 240 255
53. D. Zhao, J.B. Watson, and C.W. Xie Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation J. Neurophysiol. 92 2004 2853 2858